An observational study in Pregnancy, sponsored by Beijing Ditan Hospital. Status unknown at 1 site in China. Open to female participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-11-03.
Sponsored by Beijing Ditan Hospital · Observational
This study is a prospective observational study. The participants including 40 pregnant women who have been filed and delivered in our hospital will enrolled, collect venous blood will be collected at different stages of pregnancy, delivery, postpartum to detect the concentration of fetal free DNA, the frequency of associated immune cells, and the expression of functional molecules, so as to explore the immunological mechanism of delivery initiation.
This study is a prospective observational study. The participants including 40 pregnant women (20 normal parturients and 20 pregnant women with threatened preterm delivery) who have been filed and delivered in our hospital will enrolled, collect venous blood will be collected before 12 weeks of pregnancy, at 24 weeks of pregnancy, at 36 weeks of pregnancy, during parturition, and at 42 days after delivery to conduct the following research: 1) Studying the frequency of peripheral blood MDSCs, pDC and NK cells and the expression of functional molecules at different stages of pregnancy (12,24,36 weeks of pregnancy), before delivery and 42 days after delivery through the expression of relevant functional molecules. 2) Detecting the levels of cytokines and chemokines in peripheral blood at different stages of pregnancy (12,24,36 weeks of pregnancy), before delivery and 42 days after delivery, including: IL-1 β, IL-6, IL-10, IL-18, TGF- β and TNF- α, GM-CSF , IL-23, IL-17, IL-13, IL-4, IL-2, IFN-, IFN-, IL-8, GRO α, GCSF, GMCSM, CCL2, CCL5, CCL26,CXCL8, CXCL12，PGE2, M-CSF, COX2, CCL3, CCL4, CXCL1, IDO, Arg-1, ROS and NO. 3) Detection of cffDNA concentration in peripheral blood at different stages of pregnancy (12,24,36 weeks of pregnancy), before delivery and 42 days after delivery. 4) Detection of frequency of MDSCs, pDC and NK cells and expression of functional molecules in placenta. 5) Frequency of peripheral blood MDSCs, pDC and NK cells, expression of functional molecules, cytokine level and cffDNA concentration in pregnant women with threatened preterm labor. 6) Collecting and studying the demographic data of pregnant women at different stages of pregnancy (12,24,36 weeks of pregnancy), before delivery and 42 days after delivery, adverse events of mothers and infants in the perinatal period, and auxiliary examination data (blood routine test, liver and kidney function, TSH, infection index of Aimei B and C, TSH, blood glucose, blood coagulation function, estrogen and progesterone levels, ultrasound, electrocardiogram, etc).
Beijing Ditan Hospital is the lead sponsor of 52 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
20 normal parturients and 20 pregnant women with threatened preterm labor who had undergone antenatal examination and delivery in Beijing Ditan Hospital were fully informed of the risks and volunteered to join the study and signed the informed consent form.
Exclusion Criteria:
20 normal parturients who had undergone antenatal examination and delivery in Beijing Ditan Hospital were fully informed of the risks and volunteered to join the study and signed the informed consent form.
20 pregnant women with threatened preterm labor who had undergone antenatal examination and delivery in Beijing Ditan Hospital were fully informed of the risks and volunteered to join the study and signed the informed consent form.
The change of the frequency of myeloid-derived suppressor cells (MDSCs) in normal pregnancy and delivery
The frequency of MDSCs in maternal blood and placenta during normal pregnancy and delivery.
Time frame: at 12 weeks of pregnancy, at 24 weeks of pregnancy, at 36 weeks of pregnancy, at parturition, and at 42 days after delivery
The change of functional molecules expression of myeloid-derived suppressor cells (MDSCs) in normal pregnancy and delivery
The expression of functional molecules of MDSCs in maternal blood and placenta during normal pregnancy and delivery.
Time frame: at 12 weeks of pregnancy, at 24 weeks of pregnancy, at 36 weeks of pregnancy, at parturition, and at 42 days after delivery
The change of the frequency of plasmacytoid dendritic cells (pDC) in normal pregnancy and delivery
The frequency of pDC in maternal blood and placenta during normal pregnancy and delivery.
Time frame: at 12 weeks of pregnancy, at 24 weeks of pregnancy, at 36 weeks of pregnancy, at parturition, and at 42 days after delivery
The change of the functional molecules expression of plasmacytoid dendritic cells (pDC) in normal pregnancy and delivery
The expression of functional molecules of pDC in maternal blood and placenta during normal pregnancy and delivery.
Time frame: at 12 weeks of pregnancy, at 24 weeks of pregnancy, at 36 weeks of pregnancy, at parturition, and at 42 days after delivery
The change of the frequency of Nature Killer (NK) cells in normal pregnancy and delivery
The frequency of NK cells in maternal blood and placenta during normal pregnancy and delivery.
Time frame: at 12 weeks of pregnancy, at 24 weeks of pregnancy, at 36 weeks of pregnancy, at parturition, and at 42 days after delivery
The change of the functional molecules expression of Nature Killer (NK) cells in normal pregnancy and delivery
The expression of functional molecules of NK cells in maternal blood and placenta during normal pregnancy and delivery.
Time frame: at 12 weeks of pregnancy, at 24 weeks of pregnancy, at 36 weeks of pregnancy, at parturition, and at 42 days after delivery
The change of the content of cffDNA in normal pregnancy and delivery
The content of cffDNA in maternal blood and placenta during normal pregnancy and delivery.
Time frame: at 12 weeks of pregnancy, at 24 weeks of pregnancy, at 36 weeks of pregnancy, at parturition, and at 42 days after delivery
The change of the frequency of myeloid-derived suppressor cells (MDSCs) in Pregnant women with threatened premature delivery
The frequency of MDSCs in maternal blood and placenta in Pregnant women with threatened premature delivery.
Time frame: at 12 weeks of pregnancy, at 24 weeks of pregnancy, at 36 weeks of pregnancy, at parturition, and at 42 days after delivery
The change of functional molecules expression of myeloid-derived suppressor cells (MDSCs) in Pregnant women with threatened premature delivery
The expression of functional molecules of MDSCs in maternal blood and placenta in Pregnant women with threatened premature delivery.
Time frame: at 12 weeks of pregnancy, at 24 weeks of pregnancy, at 36 weeks of pregnancy, at parturition, and at 42 days after delivery
The change of the frequency of plasmacytoid dendritic cells (pDC) in Pregnant women with threatened premature delivery
The frequency of pDC in maternal blood and placenta in Pregnant women with threatened premature delivery.
Time frame: at 12 weeks of pregnancy, at 24 weeks of pregnancy, at 36 weeks of pregnancy, at parturition, and at 42 days after delivery
The change of functional molecules expression of plasmacytoid dendritic cells (pDC) in Pregnant women with threatened premature delivery
The expression of functional molecules of pDC in maternal blood and placenta in Pregnant women with threatened premature delivery.
Time frame: at 12 weeks of pregnancy, at 24 weeks of pregnancy, at 36 weeks of pregnancy, at parturition, and at 42 days after delivery
The change of frequency of Nature Killer (NK) cells in Pregnant women with threatened premature delivery
The frequency of NK cells in maternal blood and placenta in Pregnant women with threatened premature delivery.
Time frame: at 12 weeks of pregnancy, at 24 weeks of pregnancy, at 36 weeks of pregnancy, at parturition, and at 42 days after delivery
The change of functional molecules expression of Nature Killer (NK) cells in Pregnant women with threatened premature delivery
The expression of functional molecules of NK cells in maternal blood and placenta in Pregnant women with threatened premature delivery.
Time frame: at 12 weeks of pregnancy, at 24 weeks of pregnancy, at 36 weeks of pregnancy, at parturition, and at 42 days after delivery
The change of the content of cffDNA in Pregnant women with threatened premature delivery
The content of cffDNA in maternal blood and placenta in Pregnant women with threatened premature delivery.
Time frame: at 12 weeks of pregnancy, at 24 weeks of pregnancy, at 36 weeks of pregnancy, at parturition, and at 42 days after delivery
This study is status unknown, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Beijing Ditan Hospital